CURE2d
RECKGIST Score May Predict Recurrence in Neurofibromatosis Type 1 GISTs
RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...
Medical Dialogues2d
Selumetinib shows Limited Efficacy in Treatment of cutaneous neurofibromatosis: JAMA
Researchers have found in a nonrandomised pilot trial that selumetinib showed a reduction in cutaneous neurofibromatosis ...
GEN - Genetic Engineering and Biotechnology News17d
Healx Candidate, SpringWorks Therapy Expand NF1 Treatment Options
Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...
Why Do Tumors Form? Scientists Challenge Long-Held Cancer Predisposition Beliefs
Genetic changes alone don’t fully explain tumor growth in NF-1, pointing to other contributing factors. This insight may ...
Business Wire18d
Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of Neurofibromatosis Type 1
Despite its impact, treatment options remain limited, with many patients facing invasive surgeries or therapies with severe side effects. A Potential Breakthrough for NF1 Patients “This trial ...
European Medical Journal4d
Evaluating Selumetinib for Treating Cutaneous Neurofibromas
Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.
C&EN29d
FDA approves drug for neurofibromatosis
The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults and children. The drug, developed by SpringWorks Therapeutics ...